Therapeutic Asset Ratings
132 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
tac01-cldn18.2
Metastatic Solid Tumor
Triumvira Immunologics, Inc.
P1/2
CC
(41)
Transcon Il-2 Β/Γ
Metastatic Solid Tumor
Ascendis Pharma Oncology Division A/S
P1/2
CC
(41)
Transcon Tlr7/8 Agonist
Metastatic Solid Tumor
Ascendis Pharma Oncology Division A/S
P1/2
CC
(41)
TRASTUZUMAB
Metastatic Solid Tumor
Ascendis Pharma Oncology Division A/S
P1/2
CC
(41)
(+)-VINCRISTINE
Metastatic Solid Tumor
GI Innovation, Inc.
P1/2
CC
(41)
yh32364
Metastatic Solid Tumor
Yuhan Corporation
P1/2
CC
(41)
Zidesamtinib
Metastatic Solid Tumor
Nuvalent Inc.
P1/2
CC
(41)
Bgb-43395
Metastatic Solid Tumor
BeOne Medicines
P1
CC
(40)
Carboplatin
Metastatic Solid Tumor
Eli Lilly and Company
P1
CC
(40)
COLCHICINUM
Metastatic Solid Tumor
Icahn School of Medicine at Mount Sinai
P1
CC
(40)
Docetaxel
Metastatic Solid Tumor
InSilico Medicine Hong Kong Limited
P1
CC
(40)
FULVESTRANT
Metastatic Solid Tumor
BeOne Medicines
P1
CC
(40)
Letrozole
Metastatic Solid Tumor
BeOne Medicines
P1
CC
(40)
rc118
Metastatic Solid Tumor
RemeGen Co., Ltd.
P1
CC
(40)
rc118 for
Metastatic Solid Tumor
RemeGen Co., Ltd.
P1
CC
(40)
89Zr-DFO-REGN5054
Metastatic Solid Tumor
Regeneron Pharmaceuticals
P1
C
(37)
ace2016
Metastatic Solid Tumor
Acepodia Biotech, Inc.
P1
C
(37)
Acm-Cpg
Metastatic Solid Tumor
National Cancer Centre, Singapore
P1
C
(37)
Adu-1805
Metastatic Solid Tumor
Sairopa B.V.
P1
C
(37)
agx101
Metastatic Solid Tumor
Angiex, Inc.
P1
C
(37)
asd141
Metastatic Solid Tumor
Ascendo Biotechnology Co., Ltd.
P1
C
(37)
azd1390
Metastatic Solid Tumor
Memorial Sloan Kettering Cancer Center
P1
C
(37)
bc3195
Metastatic Solid Tumor
Biocity Biopharmaceutics Co., Ltd.
P1
C
(37)
Bgb-A3055
Metastatic Solid Tumor
BeiGene
P1
C
(37)
Bgb-B3227
Metastatic Solid Tumor
BeiGene
P1
C
(37)
Showing 51 to 75 of 132 assets
Previous
Page 3 of 6
Next
